Status:
RECRUITING
Pharmacogenomics for Better Treatment of Fungal Infections in Cancer
Lead Sponsor:
The University of Queensland
Collaborating Sponsors:
Metro North Hospital and Health Service
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Conditions:
Fungal Infection
Haematological Malignancy
Eligibility:
All Genders
2+ years
Phase:
PHASE2
Brief Summary
This project aims to address invasive fungal infections in patients with blood cancer, by precision dosing of voriconazole based on CYP2C19 genotype testing with Bayesian dose-forecasting dosing softw...
Detailed Description
Participants will be randomly assigned to standard care or precision care. Current standard of care at trial-site institutions uses weight-based (mg/kg) initial dosing of voriconazole, with dose adjus...
Eligibility Criteria
Inclusion
- Age ≥ 2 years.
- Written informed consent obtained.
- Decision to prescribe voriconazole.
- Diagnosed with haematological malignancy or disorder.
- Admitted to a trial site, or sufficient outpatient follow-up appointments are feasible
Exclusion
- Post-allogeneic haematopoietic stem cell transplant (HCT) patient, without access to pre HCT DNA
- Death is likely imminent within 7 days.
- Previously randomised to this trial
Key Trial Info
Start Date :
April 14 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 2 2026
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT06510699
Start Date
April 14 2025
End Date
September 2 2026
Last Update
November 19 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Fred Hutchinson Cancer Centre
Seattle, Washington, United States, 908109-1024
2
Sydney Children's Hospital Network
Sydney, New South Wales, Australia, 21452031
3
Westmead Hospital
Sydney, New South Wales, Australia, 2145
4
Royal Brisbane & Women's Hospital
Brisbane, Queensland, Australia, 4029